Briacell, Receptor.AI to work on kinase inhibitors

Dr. William Williams reports BRIACELL AND RECEPTOR.AI TO COLLABORATE ON AI DRIVEN SMALL MOLECULE CANCER THERAPEUTICS Briacell Therapeutics Corp.'s subsidiary, BriaPro Therapeutics Corp., has initiated a research collaboration with Receptor.AI, an artificial-intelligence-driven drug discovery company, to design anti-cancer isoform-selective kinase inhibitors for multiple cancer indications. The collaboration will integrate AI-driven molecular design expertise and BriaPro's proprietary technology to expand BriaPro's small-molecule pipeline and accelerate the development of selective kinase inhibitors that may enhance immune-mediated tumour targeting and improve cancer patient outcomes. "This partnership marks an important step in Briacell's strategic expansion beyond cell-based immunotherapy into small-molecule discovery, reinforcing its mission to deliver differentiated and complementary approaches to cancer treatment," stated Dr. William V. Williams, president and chief executive officer of Briacell and BriaPro. "Kinase selectivity, down to the isoform level, remains one of the hardest optimization problems in oncology," said Dr. Alan Nafiev, chief executive officer and founder of Receptor.AI. "This collaboration is about bringing disciplined, AI-first molecular design and rigorous ADMET [chemical absorption, distribution, metabolism, excretion and toxicity] constraints to Briacell's oncology programs, enhancing precision and translational confidence from the earliest stages of discovery." Receptor.AI has developed a multiplatform ecosystem for AI-enabled drug discovery, integrating small-molecule, peptide and induced-proximity technologies into a unified framework that accelerates therapeutic innovation across modalities. Within the collaboration, Receptor.AI will harness its small-molecule discovery platform to drive target assessment, hit identification and lead optimization, with a particular focus on achieving precise isoform selectivity among closely related kinases. About Briacell Therapeutics Corp. Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. About BriaPro Therapeutics Corp. BriaPro Therapeutics is a preclinical-stage immunotherapy company developing binding agents and proteins designed to enhance the ability of the body's own cancer-fighting cells to eliminate tumours. BriaPro is a wholly owned subsidiary of Briacell Therapeutics. We seek Safe Harbor.